Emerald Health Sciences Inc. - 10 Nov 2022 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
10%+ Owner
Signature
/s/ Stephen Hall, CFO of Emerald Health Sciences Inc.
Issuer symbol
SKYE
Transactions as of
10 Nov 2022
Net transactions value
+$1,880,141
Form type
4
Filing time
17 Mar 2023, 14:52:02 UTC
Previous filing
31 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Award $282,905 +16,641,486 +15% $0.0170 128,028,737 22 Feb 2023 Direct
transaction SKYE Common Stock Award $1,597,236 +41,379,164 +32% $0.0386 169,407,901 22 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Warrants Other $0 +9,141,486 $0.000000 9,141,486 10 Nov 2022 Common Stock 9,141,486 $0.1510 Direct F1
transaction SKYE Warrants Disposed to Issuer $0 -9,141,486 -100% $0.000000* 0 22 Feb 2023 Common Stock 9,141,486 $0.0170 Direct
transaction SKYE Warrants with Credit Facility of Oct 5, 2018 Purchase $0 -2,500,000 -100% $0.000000* 0 22 Feb 2023 Common Stock 2,500,000 $0.0386 Direct
transaction SKYE Warrants with Credit Facility of Oct 5, 2018 - T2 Disposed to Issuer $0 -2,500,000 -100% $0.000000* 0 22 Feb 2023 Common Stock 2,500,000 $0.0386 Direct F2
transaction SKYE Warrants with Credit Facility of Oct 5, 2018 - T3 Disposed to Issuer $0 -2,500,000 -100% $0.000000* 0 22 Feb 2023 Common Stock 2,500,000 $0.0386 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock.
F2 Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.